Latest / Cork News Today | 2 Min News | The Daily News Now!
HSE Skyclarys Funding Decision Today | Cork News
The HSE is poised to make a high-stakes decision on whether to fund Skyclarys, a life-changing but astronomically expensive drug for Friedreich’s ataxia patients—costing €288,000 per patient annually. After a recent advisory group recommendation against funding, political pressure has mounted, with the Taoiseach meeting affected families and the Tanaiste stressing the need for a robust, independent system to handle future breakthrough therapies. For patients and their communities, today’s verdict could mean hope—or heartbreak. Listen in comfort:Get a discount on a Soli Pillow…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.